Date of Preparation: July 15, 2011   

<table><tr><td rowspan=2 colspan=1>Meridian</td><td rowspan=1 colspan=4>K112048: Request for Additional InformationAttachment 009: Revised 510(k) Summary</td></tr><tr><td rowspan=1 colspan=1>Product Information:</td><td rowspan=1 colspan=3>ImmunoCard C. difficile GDH</td></tr><tr><td rowspan=1 colspan=1>Bioscience, Inc.</td><td rowspan=1 colspan=1>Date:</td><td rowspan=1 colspan=1>November 29, 2011</td><td rowspan=1 colspan=1>DocumentRevision:</td><td rowspan=1 colspan=1>002</td></tr></table>

510(k) number:

Submitter: Submitter's address:

Meridian Bioscience, Inc   
3471 River Hills Drive   
Cincinnati, Ohio 45244   
Susan Bogar   
(513) 271-3700

Contact: Contact number:

Device name: Common name: Classification:

ImmunoCard C. difficile GDH   
Enzyme Immunoassay for C. difficile Common Antigen   
Antigen, C. difficile   
MCB, CFR Section 866.2660

# Predicate device:

KO53572: TECHLAB C. DIFF QUIK CHEK®

Reference comparator:

Bacterial culture

# Description of the device:

ImmunoCard C. difficile GDH is a rapid qualitative enzyme immunoassay screening test to detect Clostridum die antig gtamat ehydrogena G, fecal specimens rom persons uspehavi ie inn he ssyconsst Car ifcGDHTet Car contaiili polyconaliC difficile GDH antibodies, ImmunoCard C. difficile GDH Positive Control, ImmunoCard C. difficile GDH Sample Diluent/Negative Control, ImmunoCard C. diffile GDH Enzyme Conjugate, ImmunoCard Wash Buffer I, and ImmunoCard Substrate I.

# Intended Use:

ImmunoCard C. dificile GDH is a rapid qualitative enzyme mmunoassy screening test to detect Clostridum difficile antigen, glutamate dehydrogenase, in fecal specimens from persons suspected of having C. ifficile on-o p toxigenic C. difficile strains and assist with the diagnosis of CDI.

<table><tr><td rowspan=2 colspan=1>Meridian</td><td rowspan=1 colspan=4>K112048: Request for Additional InformationAttachment 009: Revised 510(k) Summary</td></tr><tr><td rowspan=1 colspan=1>Product Information:</td><td rowspan=1 colspan=3>ImmunoCard C. difficile GDH</td></tr><tr><td rowspan=1 colspan=1>Bioscience, Inc.</td><td rowspan=1 colspan=1>Date:</td><td rowspan=1 colspan=1>November 29, 2011</td><td rowspan=1 colspan=1>DocumentRevision:</td><td rowspan=1 colspan=1>002</td></tr></table>

Table 1: Comparison to predicate device.   

<table><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>ImmunoCard C. difficile GDH</td><td rowspan=1 colspan=1>TECHLAB C. DIFF QUIK CHEK</td></tr><tr><td rowspan=1 colspan=1>Test Format</td><td rowspan=1 colspan=1>Rapid EIA</td><td rowspan=1 colspan=1>Rapid EIA</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>EY</td></tr><tr><td rowspan=1 colspan=1>Qualitative/Quantitative</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>Qualitative</td></tr><tr><td rowspan=1 colspan=1>Target Antigen</td><td rowspan=1 colspan=1>Clostridium difficile glutamatedehydrogenase</td><td rowspan=1 colspan=1>Clostridium difficile glutamatedehydrogenase</td></tr><tr><td rowspan=1 colspan=1>Screening, Diagnostic, orIdentification Test</td><td rowspan=1 colspan=1>Screening</td><td rowspan=1 colspan=1>Screening</td></tr><tr><td rowspan=1 colspan=1>Specimen Types</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Human Stool Unpreserved</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>Reagents/Components</td><td rowspan=1 colspan=1>ImmunoCard C. difficile GDH Test CardsImmunoCard C. difficile GDH EnzymeConjugateImmunoCard Wash Buffer IImmunoCard Substrate IImmunoCord C. difficile GDH SampleDiluent/Negative ControlImmunoCard C. difficile GDH PositiveControlPlastic transfer pipettes</td><td rowspan=1 colspan=1>Membrane DevicesEnzyme ConjugateWash BufferSubstrateDiluentPositive ControlDisposable plastic transfer pipettes</td></tr><tr><td rowspan=1 colspan=1>Diagnostic Marker</td><td rowspan=1 colspan=1>EY</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Antibody</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>Antibody Sources</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Test Card</td><td rowspan=1 colspan=1>Rabbit polyclonal</td><td rowspan=1 colspan=1>Polyclonal</td></tr><tr><td rowspan=1 colspan=1>Enzyme Conjugate</td><td rowspan=1 colspan=1>Mouse monoclonal</td><td rowspan=1 colspan=1>Mouse monoclonal</td></tr><tr><td rowspan=1 colspan=1>Sample Preparation</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>EY</td></tr><tr><td rowspan=1 colspan=1>Unpreserved liquid/semi-solidstool</td><td rowspan=1 colspan=1>1. 25 uL of thoroughly mixed stool into 200μL Sample Diluent. Vortex for 10 seconds.2. Add 3 drops of Enzyme Conjugate to thesample.3. Incubate diluted sample at 20-26 C for 15minutes.</td><td rowspan=1 colspan=1>1. 1 drop of Enzyme Conjugate into S00 μLDiluent2. 25 µL specimen into Diluent-Conjugatemixture. Mix with transfer pipette.</td></tr><tr><td rowspan=1 colspan=1>Solid stool</td><td rowspan=1 colspan=1>1. Add ~2mm diameter portion ofthoroughly mixed stool into 200 μL SampleDiluent and vortex for 10 seconds.2. Add 3 drops of Enzyme Conjugate to thesample.</td><td rowspan=1 colspan=1>1. Add 500 μL Diluent to a clean tube.2. Add 1 drop Conjugate to the Diluent tube.3. Transfer ~2mm diameter portion ofspecimen into the Diluent-Conjugate mixtureand emulsify the specimen using theapplicator stick.</td></tr><tr><td rowspan=1 colspan=1>Testing Time</td><td rowspan=1 colspan=1>Approximately 25 minutes</td><td rowspan=1 colspan=1>Approximately 25 minutes</td></tr><tr><td rowspan=1 colspan=1>Equipment</td><td rowspan=1 colspan=1>EY</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>General Laboratory Equipment</td><td rowspan=1 colspan=1>VortexInterval timerApplicator sticksSmall test tubesDisposable latex gloves</td><td rowspan=1 colspan=1>Pipettor and tipsVortexInterval timerApplicator sticksSmall test tubesDisposable latex gloves</td></tr><tr><td rowspan=1 colspan=1>Reading Method</td><td rowspan=1 colspan=1>Visual</td><td rowspan=1 colspan=1>Visual</td></tr></table>

<table><tr><td rowspan=2 colspan=1>Meridian</td><td rowspan=1 colspan=4>K112048: Request for Additional InformationAttachment 009: Revised 510(k) Summary</td></tr><tr><td rowspan=1 colspan=1>Product Information:</td><td rowspan=1 colspan=3>ImmunoCard C. difficile GDH</td></tr><tr><td rowspan=1 colspan=1>Bioscience, Inc.</td><td rowspan=1 colspan=1>Date:</td><td rowspan=1 colspan=1>November 29, 2011</td><td rowspan=1 colspan=1>DocumentRevision:</td><td rowspan=1 colspan=1>002</td></tr></table>

Table 1: Comparison to predicate device contd.   

<table><tr><td colspan="3">Results Interpretation</td></tr><tr><td rowspan="7">Visual Read</td><td>Negative: Blue color in the CONTROL</td><td>Negative: Single blue line visible on the</td></tr><tr><td>reaction port only.</td><td>CONTROL side of the reaction window only.</td></tr><tr><td>Positive: Blue color in the TEST and</td><td>Positive: Blue line visible on the TEST side</td></tr><tr><td>CONTROL reaction ports.</td><td>along with a blue fine visible on the</td></tr><tr><td>Invalid: No detectable blue color in the</td><td>CONTROL side.</td></tr><tr><td>CONTROL reaction port or a blue ring on</td><td>Invalid: Single line visible on the TEST side of</td></tr><tr><td>the plastic frame surrounding the TEST port</td><td>the reaction window or no lines visible in the</td></tr></table>

# Performance Comparison, Non-Clinical Tests

# Analytical Sensitivity

Sensitivity studies were designed to determine with $9 5 \%$ confidence the analytical limit of detection (LoD) of C. iH ntdiutistol mathe nalyticl nstiviy  hi ssy a basd $( 9 5 \% )$ levels of the measurand when spiked in stool: $1 0 n \times 8 / m l$

# Interference Testing

S   l i ti Te cni os pl as pe  i  ceti pl at $1 0 n \geq / m L$ , the limit of detection for this assay. Potentially interfering substances were added at final concentrations of $5 \%$ V/V or greater. Dilution Controls for each sample were prepared by adding a phosphate

The following substances, at the specified saturated solvent/diluent concentrations, do not interfre with ImmunoCard C. difficile GDH test results in the final concentrations listed: Barium sulfate $( 5 m g / m L )$ , Fecal fat (2.65 mg stearic acid and $1 . 3 \mathsf { m } \mathsf { g }$ palmitic acid $m L$ , Hemoglobin $( 3 . 2 m g / m L )$ , Imodium $A D ^ { \otimes }$ (Loperamide HCI) $ { - } \{ 6 . 6 7 \times 1 0 \}$ $\beta _ { \mathrm { \ m g / m L ) } }$ , Kaopectate® (Bismuth subsalicylate) $( 0 . 8 7 m g / m L )$ , Metronidazole $\{ 1 2 . 5 ~ \mathsf { m g } / \mathsf { m L } \}$ ,Mucin $\{ 3 . 3 3 \ m g / \mathsf { m L } \} ,$ Mylanta® (Aluminum hydroxide w/ magnesium hydroxide) $( 4 . 2 m g / m L )$ , Pepto-Bismol® (Bismuth subsalicylate) $\{ 0 . 8 7 \ m g / m L \} ,$ Polyethylene glycol $( 7 9 . 0 5 m g / m L )$ , Prilosec® (Omeprazole) $\{ 0 . 5 \ m g / m L \}$ , Simethicone (0.625 $m g / m L )$ , Tagamet® (Cimetidine) $( 0 . 5 \ m g / m L )$ , Tums® (Calcium carbonate) $( 5 . 0 \ m g / m L )$ , Vancomycin HCI (2.5 $m g / m L )$ , Whole blood $( 4 0 \% )$ , White blood cells $( 5 \% )$ .

# Cross-reactivity Study

ocina e eal u   p The contrived positive specimen was prepared from a pool of donor stools that was confirmed negative. The contrived positive sample was prepared by spiking a confirmed negative sample with C. difficile GDH at $1 0 n g / m L ,$ EPY of $1 . 2 \times 1 0 ^ { 8 } C F U / m L$ (bacteria or fungi) or a final concentration greater than $1 \times 1 0 ^ { 5 } \top \mathsf { C } | \mathsf { D } _ { 5 0 } / \mathsf { m L }$ (viruses). Dilution c    e n a ps organisms.

<table><tr><td rowspan="2">Meridian</td><td colspan="4">K112048: Request for Additional Information Attachment 009: Revised 510(k) Summary</td></tr><tr><td>Product Information:</td><td colspan="3">ImmunoCard C. difficile GDH</td></tr><tr><td>Bioscience, Inc.</td><td>Date:</td><td>November 29, 2011</td><td>Document Revision:</td><td>002</td></tr></table>

The followicoanis a e dicacontrtns  otinte wi ar C GDH test reults:Aernas hyrophia, Bacius cerus Bacillus sbtis, Bactroids fragi Cpybacc, Campylobacterfetus, Campylobacter juni Candidaalbicans, Citrobactrfreund Clostridu biferentans, Clostridium butyricum, Clostridium haemolyticum, Clostridium histolyticum, Clostridium novyi, Clostridum peingens Closrdiu ticClostu ordel Clostridiu sorgenesClostdiu eta Enter agees, Enteba cloa, Enteococus faecal Escerca col Escherica col 157:7, Escca hermannii, Escherichia fergusonii, Helicobacter pyl Klebsiella pneumoniae, Lactococus lact, Listia monocytogenes, Peptostreptococcus anaerobius, Plesiomonas shigelloides, Porphyromonas asaccharolytica, Proteus vulgaris Pseudomonas aeruginosa, seudomonas fuorescens, Salmonella Group B, Salmonella Group C, Salmonella Group D, Salonela GroupE, Serratia qufaciens, Serratia arccens Shigella boyd, higella flex Shiglla sonnei, Staphylococcus ureus, Staphylococcus epidermidis, Vibrio parheolyticus, Yersia olia Aei Tp0 Aevius Typ  Coxvi Sra  Ehov ra 0Roviu Strain WA.

Stol spiked with Staphylococcus aureus Cowan Strain ) wee found o be cross-reactive with Imunoard C.   
difficile GDH.

# Strain Reactivity

The  i ccuin  we n o pos s concentration of $1 . 2 \times 1 0 7 \ : \mathsf { C F U / m l }$ with the ImmunoCard C. difficile GDH assay:

Toxigenic C. difficile strains: 8864, 10463, 43598, 2004052, 2004111, 2004118, 2004205, 2004206, 2005070, 2005257, 2005325, 2006240, 2007431, 2007435, 2007858, 2008016, 2008029, 2008162, 2008188, 2008341, 200831, 2009018, 2009065, 2009066, 2009099, 2009132, 2009155, 2009277, B1, BI17, BI8, BK6, CF1, G1, J7, K12, Y1

Non-toxigenic C. difficile strains: 11186, 234, 586, 611, 620, 2C62, 2C165, C122, UNC19904, X15076

# Performance Comparison, Clinical Tests

Clinical trials for the ImmunoCard C. difficile GDH assay were conducted April  June 2011. Performance characristi  he ImoCar C.c GH assay were determin ycomparison to bacteal Ce cultur. Independent clnical st sis located in he Midwestern, Southeastern, Souhwestern and Wesern ni Saal   qal pt p; a  w collected. Samples were collected from 446 $( 4 5 . 7 \% )$ males and 529 $( 5 4 . 3 \% )$ females and categorized as solid $\{ 1 7 . 1 \% \}$ ,semi-solid $( 5 0 . 8 \% )$ , bloody $\{ 0 . 5 \% \}$ and watery $( 3 1 . 5 \% )$ . The age groups of patients range from 14 days to 11 years. No differences in test performance were observed based on patient age, gender, or geographic location. Overall sensitivity was determined to be $9 7 . 6 \% ( 9 5 \% ) C 1 : 9 3 . 3 - 9 9 . 2 \%$ Overall specificity was determined to be $3 7 . 0 \% ( 9 5 \% 0 ) [ 1 : 8 4 . 6 - 9 0 . 1 \% )$ . Subsequent tables show overall assay performance as well as performance by clinical site and patient age.

<table><tr><td rowspan=2 colspan=1>Meridian</td><td rowspan=1 colspan=4>K112048: Request for Additional InformationAttachment 009: Revised 510(k) Summary</td></tr><tr><td rowspan=1 colspan=1>Product Information:</td><td rowspan=1 colspan=3>ImmunoCard C. difficile GDH</td></tr><tr><td rowspan=1 colspan=1>Bioscience, Inc.</td><td rowspan=1 colspan=1>Date:</td><td rowspan=1 colspan=1>November 29, 2011</td><td rowspan=1 colspan=1>DocumentRevision:</td><td rowspan=1 colspan=1>002</td></tr></table>

Table 2: Performance Characteristics for ImmunoCard C. difficile GDH   

<table><tr><td rowspan=2 colspan=1>Culture</td><td rowspan=1 colspan=3>ImmunoCard C. difficile GDH</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>124</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>127</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>738</td><td rowspan=1 colspan=1>848</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>234</td><td rowspan=1 colspan=1>741</td><td rowspan=1 colspan=1>975</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>124/127</td><td rowspan=1 colspan=1>97.6%</td><td rowspan=1 colspan=1>93.3 - 99.2%</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>738/848</td><td rowspan=1 colspan=1>87.0%</td><td rowspan=1 colspan=1>84.6 - 90.1%</td></tr><tr><td rowspan=1 colspan=1>Correlation</td><td rowspan=1 colspan=1>862/975</td><td rowspan=1 colspan=1>88.4%</td><td rowspan=1 colspan=1>86.2 - 90.3%</td></tr></table>

Table 3: Performance Characteristics by Site   

<table><tr><td rowspan=1 colspan=1>Clinical TrialSite</td><td rowspan=1 colspan=1>ImmunoCardC. difficileGDH/Culture</td><td rowspan=1 colspan=1>% Sensitivity</td><td rowspan=1 colspan=1>95% Cl</td><td rowspan=1 colspan=1>ImmunoCardC. difficileGDH/Culture</td><td rowspan=1 colspan=1>% Specificity</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>32/32</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>89.3 - 100.0%</td><td rowspan=1 colspan=1>165/205</td><td rowspan=1 colspan=1>80.5%</td><td rowspan=1 colspan=1>74.5 -85.3%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>39/41</td><td rowspan=1 colspan=1>95.1%</td><td rowspan=1 colspan=1>83.9-98.7%</td><td rowspan=1 colspan=1>257/290</td><td rowspan=1 colspan=1>88.6%</td><td rowspan=1 colspan=1>84.4-91.8%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>35/36</td><td rowspan=1 colspan=1>97.2%</td><td rowspan=1 colspan=1>85.8-99.5%</td><td rowspan=1 colspan=1>140/168</td><td rowspan=1 colspan=1>83.3%</td><td rowspan=1 colspan=1>77.0 -88.2%</td></tr><tr><td rowspan=1 colspan=1>Site 4</td><td rowspan=1 colspan=1>8/8</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>67.6 - 100.0%</td><td rowspan=1 colspan=1>76/80</td><td rowspan=1 colspan=1>95.0%</td><td rowspan=1 colspan=1>87.8 -98.0%</td></tr><tr><td rowspan=1 colspan=1>Site 5</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>72.2 - 100.0%</td><td rowspan=1 colspan=1>100/105</td><td rowspan=1 colspan=1>95.2%</td><td rowspan=1 colspan=1>89.3-97.9%</td></tr></table>

Table 4: Performance Characteristics by Patient Age   

<table><tr><td rowspan=1 colspan=1>Patient Age</td><td rowspan=1 colspan=1>ImmunoCardC. difficileGDH/Culture</td><td rowspan=1 colspan=1>Sensitivity %</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>ImmunoCardC. difficileGDH/Culture</td><td rowspan=1 colspan=1>Specificity %</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>≤ 5 years</td><td rowspan=1 colspan=1>41/41</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>91.4-100.0%</td><td rowspan=1 colspan=1>129/168</td><td rowspan=1 colspan=1>76.8%</td><td rowspan=1 colspan=1>69.8-82.5%</td></tr><tr><td rowspan=1 colspan=1>6-21 years</td><td rowspan=1 colspan=1>30/31</td><td rowspan=1 colspan=1>96.8%</td><td rowspan=1 colspan=1>83.8-99.4%</td><td rowspan=1 colspan=1>179/208</td><td rowspan=1 colspan=1>86.1%</td><td rowspan=1 colspan=1>80.7-90.1%</td></tr><tr><td rowspan=1 colspan=1>22-59 years</td><td rowspan=1 colspan=1>21/22</td><td rowspan=1 colspan=1>95.5%</td><td rowspan=1 colspan=1>78.2-99.2%</td><td rowspan=1 colspan=1>213/233</td><td rowspan=1 colspan=1>91.4%</td><td rowspan=1 colspan=1>87.1-94.4%</td></tr><tr><td rowspan=1 colspan=1>≥ 60 years</td><td rowspan=1 colspan=1>32/33</td><td rowspan=1 colspan=1>97.0%</td><td rowspan=1 colspan=1>84.7-99.5%</td><td rowspan=1 colspan=1>217/239</td><td rowspan=1 colspan=1>90.8%</td><td rowspan=1 colspan=1>86.5-93.8%</td></tr></table>

<table><tr><td rowspan="2">Meridian</td><td colspan="4">K112048: Request for Additional Information Attachment 009: Revised 510(k) Summary</td></tr><tr><td>Product Information:</td><td>ImmunoCard C. difficile GDH</td><td></td><td></td></tr><tr><td>Bioscience, Inc.</td><td>Date:</td><td>November 29, 2011</td><td>Document Revision:</td><td>002</td></tr></table>

# Reproducibility

Reproducibility panels were performed by three clinical laboratories using blinded coded panels. Samples were randomly sorted within each panel to mask identities. Each panel consisted of 3 contrived moderately positive specimens, 3 contrived low positive samples, 3 contrived high negative specimens, and 1 natural negative specimen. Panels were tested at three independent laboratories by two operators at each laboratory, twice each day over 5 non-consecutive days. The overal correlation for the ImmunoCard C. difficile GDH reproducibility study was $9 9 . 7 \%$ $( 9 8 . 1 - 9 9 . 9 \% )$ . The correlation between expected and achieved results for the moderate positive, low positive and negative specimens was $1 0 0 . 0 \% \left( 9 8 . 2 - 1 0 0 . 0 \% \right)$ .The correlation for the high negative specimen was $9 8 . 9 \%$ $9 4 . 0 - 9 9 . 8 \% )$ . Tables 5-7 contain the reproducibility data for the 3 sites.

<table><tr><td rowspan="2">Meridian</td><td colspan="4">K112048: Request for Additional In.- . .nation Attachment 009: Revised 510(k) Summary</td></tr><tr><td>Product Information:</td><td>ImmunoCard C. difficile GDH</td><td></td><td></td></tr><tr><td>Bioscience, Inc.</td><td>Date:</td><td>November 29, 2011</td><td>Document Revision:</td><td>002</td></tr></table>

<table><tr><td rowspan=4 colspan=1>Sample ID</td><td rowspan=4 colspan=2>Sample Qual.Result</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>Day 1Run 1</td><td rowspan=2 colspan=1>Day 1Run 2</td><td rowspan=2 colspan=1>Day 2Run 1</td><td rowspan=2 colspan=1>Day 2Run 2</td><td rowspan=2 colspan=1>Day 3Run 1</td><td rowspan=2 colspan=1>Day 3Run 2</td><td rowspan=2 colspan=1>Day 4Run 1</td><td rowspan=2 colspan=1>Day 4Run 2</td><td rowspan=2 colspan=1>Day 5Run 1</td><td rowspan=2 colspan=1>Day 5Run 2</td></tr><tr></tr><tr><td rowspan=1 colspan=1>(EK)*</td><td rowspan=1 colspan=1>(EEG)*</td><td rowspan=1 colspan=1>(EK)*</td><td rowspan=1 colspan=1>(EEG)*</td><td rowspan=1 colspan=1>(EK)*</td><td rowspan=1 colspan=1>(EEG)*</td><td rowspan=1 colspan=1>(EK)*</td><td rowspan=1 colspan=1>(EEG)*</td><td rowspan=1 colspan=1>(EK)*</td><td rowspan=1 colspan=1>(EEG)*</td></tr><tr><td rowspan=1 colspan=1>Positive Control</td><td rowspan=1 colspan=2>Positive</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Negative Control</td><td rowspan=1 colspan=2>Negative</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Moderate Positive 1</td><td rowspan=3 colspan=2>Positive</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>POs</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Moderate Positive 2</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Moderate Positive 3</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>POs</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Low Positive 1</td><td rowspan=3 colspan=2>Positive</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Low Positive 2</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Low Positive 3</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>High Negative 1</td><td rowspan=2 colspan=2>Negative</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>High Negative 2</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>High Negative 3</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Negative 1</td><td rowspan=1 colspan=2>Negative</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=3>Percent Correlation</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>90.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=3>Correlation of cut off Specimens</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>83.3%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td></tr></table>

<table><tr><td rowspan=3 colspan=1>MeridianBioscience, Inc.</td><td rowspan=1 colspan=4>K112048: Request for Additional InformationAttachment 009: Revised 510(k) Summary</td></tr><tr><td rowspan=1 colspan=1>Product Information:</td><td rowspan=1 colspan=3>ImmunoCard C. difficile GDH</td></tr><tr><td rowspan=1 colspan=1>Date:</td><td rowspan=1 colspan=1>November 29, 2011</td><td rowspan=1 colspan=1>Document Revision:</td><td rowspan=1 colspan=1>002</td></tr></table>

<table><tr><td rowspan=3 colspan=1>Sample ID,&#x27;</td><td rowspan=3 colspan=3>Sample Qual.Result</td><td rowspan=3 colspan=1>Day 1Run 1(JM)*</td><td rowspan=2 colspan=1>Day 1Run 2</td><td rowspan=2 colspan=1>Day 2Run 1</td><td rowspan=2 colspan=1>Day 2Run 2</td><td rowspan=2 colspan=1>Day 3Run 1</td><td rowspan=2 colspan=1>Day 3Run 2</td><td rowspan=2 colspan=1>Day 4Run 1</td><td rowspan=2 colspan=1>Day 4Run 2</td><td rowspan=2 colspan=1>Day 5Run 1</td><td rowspan=2 colspan=1>Day 5Run 2</td><td></td></tr><tr><td></td></tr><tr><td rowspan=1 colspan=1>(DS)*</td><td rowspan=1 colspan=1>(M)*</td><td rowspan=1 colspan=1>(DS) *</td><td rowspan=1 colspan=1>(JM)</td><td rowspan=1 colspan=1>(DS)*</td><td rowspan=1 colspan=1>(JM)*</td><td rowspan=1 colspan=1>(DS)*</td><td rowspan=1 colspan=1>(JM)*</td><td rowspan=1 colspan=1>(DS)*</td><td></td></tr><tr><td rowspan=1 colspan=1>Positive Control</td><td rowspan=1 colspan=3>Positive</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td></td></tr><tr><td rowspan=1 colspan=1>Negative Control</td><td rowspan=1 colspan=3>Negative</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td></td></tr><tr><td rowspan=1 colspan=1>Moderate Positive 1</td><td rowspan=3 colspan=3>Positive</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td></td></tr><tr><td rowspan=1 colspan=1>Moderate Positive 2</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td></td></tr><tr><td rowspan=1 colspan=1>Moderate Positive 3</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td></td></tr><tr><td rowspan=1 colspan=1>Low Positive 1</td><td rowspan=3 colspan=3>Positive</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td></td></tr><tr><td rowspan=1 colspan=1>Low Positive 2</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td></td></tr><tr><td rowspan=1 colspan=1>Low Positive 3</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td></td></tr><tr><td rowspan=1 colspan=1>High Negative 1</td><td rowspan=2 colspan=3>Negative</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td></td></tr><tr><td rowspan=1 colspan=1>High Negative 2</td><td rowspan=2 colspan=3>Negative</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>High Negative 3</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td></td></tr><tr><td rowspan=1 colspan=1>Negative 1</td><td rowspan=1 colspan=3>Negative</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td></td></tr><tr><td rowspan=1 colspan=4>Percent Correlation</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td></td></tr><tr><td rowspan=1 colspan=4>Correlation of cut off Specimens</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td></td></tr></table>

aanpSan - San 'aanicod  cod :nuaSal

<table><tr><td rowspan=4 colspan=1>Sample ID</td><td rowspan=4 colspan=3>Sample Qual.Result</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>Day 1Run 1</td><td rowspan=2 colspan=1>Day 1Run 2</td><td rowspan=2 colspan=1>Day 2Run 1</td><td rowspan=2 colspan=1>Day 2Run 2</td><td rowspan=2 colspan=1>Day 3Run 1</td><td rowspan=2 colspan=1>Day 3Run 2</td><td rowspan=2 colspan=1>Day 4Run 1</td><td rowspan=2 colspan=1>Day 4Run 2</td><td rowspan=2 colspan=1>Day 5Run 1</td><td rowspan=2 colspan=1>Day 5Run 2</td></tr><tr></tr><tr><td rowspan=1 colspan=1>(KE)*</td><td rowspan=1 colspan=1>(LS)*</td><td rowspan=1 colspan=1>(KE)*</td><td rowspan=1 colspan=1>(LS) *</td><td rowspan=1 colspan=1>(KE)*</td><td rowspan=1 colspan=1>(LS)*</td><td rowspan=1 colspan=1>{(KE)*</td><td rowspan=1 colspan=1>(LS)*</td><td rowspan=1 colspan=1>{(KE) *</td><td rowspan=1 colspan=1>(LS)*</td></tr><tr><td rowspan=1 colspan=1>Positive Control</td><td rowspan=1 colspan=3>Positive</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Negative Control</td><td rowspan=1 colspan=3>Negative</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Moderate Positive 1</td><td rowspan=3 colspan=3>Positive</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Moderate Positive 2</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Moderate Positive 3</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Low Positive 1</td><td rowspan=2 colspan=3>Positive</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Low Positive 2</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Low Positive 3</td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>High Negative 1</td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>High Negative 2</td><td rowspan=2 colspan=3>Negative</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>High Negative 3</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Negative 1</td><td rowspan=1 colspan=3>Negative</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=4>Percent Correlation</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=4>Correlation of cut off Specimens</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td></tr></table>

Meridian Bioscience, Inc.   
c/o Susan Bogar   
Product Quality Assurance Manager 3471 River Hills Drive   
Cincinnati, OH 45244

Re: K112048 Trade/Device Name: ImmunoCard™ C. difficile GDH Assay Regulation Number: 21 CFR $\$ 866.2660$ Regulation Name: Microorganism Differentiation and Identification Device Regulatory Class: Class I Product Codes: MCB Dated: December 7, 2011 Received: December 8, 2011

Dear Ms. Bogar:

We have reviewed your Section $5 1 0 ( \mathbf { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice

requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html. Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Devices   
Evaluation and Safety   
Center for Devices and Radiological Health

![](images/eafd7e96bd56ac8a95e9e1e00c3057d19cdd1ade0346186e67e88c2cd15eef51.jpg)

# Indications for Use Form

510(k) Number (if known): K11 2048

Device Name: _ ImmunoCard C. difficile GDH

Indications for Use:

ImmunoCard C. difficile GDH is a rapid qualitative enzyme immunoassay screening test to detect Clostridium difficile antigen, glutamate dehydrogenase, in fecal specimens from persons suspected of having C. difficile infection (CDl). This test does not distinguish between toxigenic and non-toxigenic strains of C. difficile. Samples from patients that produce positive results with this test must be further tested with an assay designed to detect toxigenic C. difficile strains and assist with the diagnosis of CDI.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/b071d1b9d65fe1fa0abaed339afacbfdc2dd306a0ae4095ec476f981620147f6.jpg)

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety.

510(k) K112048